See What HealthDay Can Do For You
Contact Us

New Drug Treats Rare Hormonal Disorder

Acromegaly causes enlarged features and organs

FRIDAY, Aug. 31, 2007 (HealthDay News) -- The U.S. Food and Drug Administration has approved Somatuline Depot (lanreotide acetate injection) to treat a rare growth hormone-related disorder called acromegaly, the agency said Friday.

The disorder, caused by an abnormal secretion of the hormone, is characterized by enlarged hands, feet, facial bones, and internal organs such as the heart and liver. If untreated, people with the disorder often die prematurely because of heart and respiratory problems, diabetes, or colon cancer, the FDA said. The disorder affects about 15,000 people in the United States and Canada.

The drug's safety and effectiveness were evaluated in two clinical trials involving 400 people. The most frequent side effects were diarrhea, gallstones, skin reactions, slow heart rate, and changes in blood sugar levels.

Samatuline Depot is marketed by Beaufour Ipsen, based in Paris, France.

More information

The FDA has more about the approval.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.